A 46-year-old man was diagnosed with pleural effusion - a case of fluid accumulation around the lungs. According to his diagnostic tests, he was a confirmed case of stage 4 adenocarcinoma of the lung ...

Personalized treatment strategies are increasingly important in managing lung cancer brain metastases, incorporating targeted therapies and immunotherapies. Stereotactic radiosurgery and whole-brain ...

Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a one-size-fits-all approach. Biomarkers serve diagnostic, prognostic, and predictive roles ...

A lung cancer diagnosis can feel frightening. And when a family member is diagnosed, you might wonder about your own risk, prompting you to ask if lung cancer is hereditary. Smoking tobacco accounts ...

Biomarker testing has the potential to streamline diagnosis, treatment planning, and anticipation of treatment risks, if done right.

For Josh Henderson, 66, of Olympia, getting genetic testing was a no-brainer. “The first time I came to Fred Hutch, my oncologist suggested it,” said the retired IT manager who received a metastatic ...

After surviving three types of cancer and having to face the harsh realities of colorectal and endometrial cancer and basal cell carcinoma, I know just how crucial early detection can be in saving ...

The FDA approved the Oncomine Dx Express Test for rapid identification of NSCLC patients eligible for Zegfrovy treatment. The test provides results in 24 hours, aiding timely therapeutic decisions and ...

Scientists in Newcastle, where the test was developed, hailed it as a "revolution" A pioneering test is improving early diagnosis for people with hereditary cancer caused by a genetic condition. Just ...

Biomarker testing is crucial for personalized oncology care, aiding in risk stratification and treatment decisions, but faces challenges in uptake and education. Multistakeholder partnerships and ...

Unlock the latest liquid biopsy market data. Explore growth drivers, precision oncology shifts, and the tech fueling ...